Navigation Links
OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
Date:4/15/2008

AMSTERDAM, April 15 /PRNewswire/ -- SynCo Bio Partners B.V., a leading GMP biopharmaceutical manufacturer, has signed a Master Services Agreement with OncoMed Pharmaceuticals, a company developing novel therapeutics that target cancer stem cells. Under the agreement, SynCo will fill and finish batches of OncoMed's lead product, antibody OMP-21M18, for use in Phase I clinical trials.

Announcing the agreement, Pierre Warffemius, CEO, said, "We are delighted that a company at the forefront of cancer therapies has recognised our expertise in biopharmaceutical processing by choosing us to fill their lead antibody for early clinical trails."

Paul J. Hastings, President and CEO of OncoMed, "We selected SynCo Bio Partners because we needed a GMP-accredited contract manufacturing organisation that had a proven track record in filling biologics. With SynCo's expertise in all aspects of biopharmaceutical manufacture, they were an ideal partner for us at this crucial stage in our development."

OncoMed recently announced that it had signed a worldwide strategic alliance with GSK to develop cancer stem cell antibody therapeutics. One of the key projects in this alliance will be the development of OncoMed's lead antibody product candidate, OMP-21M18, a monoclonal antibody, which is scheduled to enter the clinic in 2008.

SynCo will fill and finish antibody OMP-21M18 at its Amsterdam-based facility. This facility is able to fill a wide range of biopharmaceuticals into vials, including protein, polysaccharide, and live-microbial-based products using the latest filling and finishing equipment.

Issued on behalf of SynCo Bio Partners by De Facto Communications

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with in-depth clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of different vaccines, live bacterial products and recombinant proteins in our state-of-the-art, GMP-licensed facilities in the last seven years.

Financially stable and focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering your product on time and to the highest quality standards. All our staff are committed to exceeding customer expectations and believe that taking a truly collaborative approach to manufacture is the key to a successful outcome.

About OncoMed Pharmaceuticals Inc.

OncoMed Pharmaceuticals is discovering and developing novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. The company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as breast, colon, prostate, and lung cancers. OncoMed is a leader in cancer stem cell research and the identification of novel cancer stem cell targets. Privately-held, the company's investors include US Venture Partners, Latterell Venture Partners, Morgenthaler Ventures, The Vertical Group, Adams Street Partners, De Novo Ventures and Bay Partners. Additional information can be found at the company's website: http://www.oncomed.com.


'/>"/>
SOURCE SynCo Bio Partners B.V.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
5. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
6. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
7. UNICEF Partners With Causes on Facebook to Launch Charity Gift Feature
8. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
9. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
10. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
11. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  The ... Nursing received an in-kind gift from ... a VeinViewer® Vision vein finder for the ... help students as they learn how to ... technology with traditional technique. ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 /PRNewswire/ ... of Pro Medicus Ltd. (ASX: PME), has announced that ... University of Florida (UF) have selected the Visage ... diagnostic viewer of the Emergent/Critical Care Imaging SIMulation ... Wisdom in Diagnostic Imaging Program (WIDI), a multi-faceted ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
Breaking Medicine Technology:
(Date:2/11/2016)... MA (PRWEB) , ... February 11, 2016 , ... The ... overpaying for IT services, what questions to ask your IT consultant before signing a ... access to your computer network. , “With companies relying heavily on e-mail and technology, ...
(Date:2/10/2016)... ... February 10, 2016 , ... President Obama’s ... Advantage organizations to deliver medical services via telehealth, estimated to generate more than ... for such language for many years. Although there is more to be ...
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team ... raise awareness of Nestlé KITKAT as the first global confectionery brand sourced from 100% ... farmers and the quality of their product, through activities that focus on better farming, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Western ... dental health services to the developmentally disabled in the Coachella Valley. , The ... a new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City Health ... (VRI). , For nearly 23 years, Heart City Health Center has provided the ...
Breaking Medicine News(10 mins):